Ibane Abasolo Olaortua I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module. Institutions of which they are part Head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Biologist Bioquímica Cross-departmental services LinkedIn Twitter Orcid Ibane Abasolo Olaortua LinkedIn Twitter Orcid Institutions of which they are part Head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Biologist Bioquímica Cross-departmental services I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.
I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB. Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease. I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).
Research lines Obtenció i us de vesícules extracel·lulars com vehicles per proteïnes i biomolècules IP: Ibane Abasolo Olaortua Pagination First page « Previous page ‹ Page 1 Current page 2 Projects Personal Técnico de Apoyo 2021 IP: Ibane Abasolo Olaortua Collaborators: Diana Fernandes de Rafael, Miriam Izquierdo Sans Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 42600 Reference: PTA2021-021005-I Duration: 01/01/2023 - 31/12/2023 EVERETT: Engineered mesenchymal stromal cell Extracellular Vesicles for immunomodulatory biotherapy and Enzyme REplacemenT Therapy IP: Ibane Abasolo Olaortua Collaborators: - Funding agency: Agence Nationale de la Recherche Funding: 0.01 Reference: EVERETT_ANR-BIOPNSE2020 Duration: 01/11/2022 - 31/10/2025 EXOPROD - Vesículas extracelulares dirigidas, como sistemas de liberación de proteínas recombinantes IP: Ibane Abasolo Olaortua Collaborators: - Funding agency: Fundación Innov. y Prosp. Salud en España - FIPSE Funding: 30000 Reference: 3969-21 Duration: 07/04/2021 - 07/12/2021 Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados IP: Ibane Abasolo Olaortua Collaborators: Marc Miquel Moltó Abad, Miriam Izquierdo Sans Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 90306.55 Reference: SLT017/20/000181 Duration: 05/07/2021 - 31/12/2024 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 … Next page › Last page »
